iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy.
Icad stock last closed at $2.37, down 1.25% from the previous day, and has decreased 54.77% in one year. It has underperformed other stocks in the Health Information Services industry by 0.2 percentage points. Icad stock is currently +54.9% from its 52-week low of $1.53, and -61.15% from its 52-week high of $6.10.
As of Feb 3, 2023, there are 25.45M ICAD shares outstanding. The market cap of ICAD is $60.31M. In the past 24 hours, 92,595 ICAD shares were traded.
You need a brokerage account in order to access the NASDAQ market and buy ICAD shares.
We believe that eToro is the best brokerage. eToro gives you:
Get $10 towards your stock purchase by creating an account with eToro now.Open eToro Account
Now that you've picked your brokerage, you'll need to fill out some personal information so you can buy ICAD stock today.
Now that you've opened your account on the stocks app, you need to deposit funds:
Check out the walkthrough below for more details transferring money into your new investment account.
Once you have identified the best place to buy Icad stock, it's critical to research their stock before you invest, so you actually understand the risk as well as the opportunity.
WallStreetZen was built to help part-time investors perform better fundamental analysis in minutes instead of hours.
You can view all of the due diligence checks on ICAD's stock page.
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge ICAD's intrinsic value.
Using relative valuations measures:
You can access additional valuation research on ICAD's stock here.
Out of 3 sell side analysts who track ICAD, the consensus analyst rating on ICAD is a Strong Buy
It's important to keep in mind that analyst forecasts are not stock recommendations, nor are they investment advice.
David Turkaly, a bottom 24% analyst from JMP Securities maintains ICAD with a buy rating and lowers their ICAD price target from $13.00 to $7.00, on Sep 1, 2022.
Frank Takkinen, a bottom 2% analyst from Lake Street maintains ICAD with a strong buy rating and lowers their ICAD price target from $13.00 to $8.00, on Aug 11, 2022.
Marie Thibault, a top 4% analyst from BTIG maintains ICAD with a strong buy rating and lowers their ICAD price target from $10.00 to $8.00, on Jun 24, 2022.
You can dig deeper into what analysts are projecting on the Icad stock forecast page.
Last year, ICAD revenue was $29.26M. Over the last five year, ICAD's revenue has gone up by 1.53% per year. This was slower than the Health Information Services industry average of 44.69%.
Learn more about ICAD's earnings and revenue performance here.
In the past year, executives and large shareholders at ICAD have sold more shares than they have bought.
Jonathan Go, Chief Technology Officer of ICAD, was the latest ICAD insider to buy. They bought $102,150.00 worth of ICAD shares on Sep 12, 2022.
Dig into more about who owns ICAD shares here.
No, Icad doesn't provide an income stream by paying out dividends.
One of the biggest reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to learn what other traders have to say.
You have two main types of orders:
Hit the Open button and your broker will execute the order.
If you need more info about investing in stocks on eToro, click the helpful video below:
Now that you own some ICAD shares, you'll want to keep up with your investment.
Create a watchlist to keep track of your ICAD stock.
To summarize, here are the 6 steps to buy Icad stock:
If you require a brokerage account, eToro is our recommended venue.Get Started with eToro Today
If you want to get the latest scoop on your new investment in Icad, hit the button below to create your watchlist.
How much does it cost to buy one Icad share?
Is now a good time to buy Icad stock?
What is the best way to buy Icad stock?